A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
Consumer Intelligence, End of Life, Facts and Figures, Health and Wellness, Reports
Over the next 15 years, adopting healthy behaviors, developing better treatments and improving access to high quality care for chronic disease would r...
Disabilities, Facts and Figures, Falls Prevention, Managed Risk, Reports
An increasing number of people in Europe and North American are expected to use personal emergency response systems (PERS), growing at an annual compo...
cheatsheet, Federal Agency Activity, Health and Wellness, Managed Risk, Memory Care Best Practices and Research, Memory Care Education
The Dementia Friendly America program entered the national stage in July when it was announced at the 2015 White House Conference on Aging. DFA cre...
End of Life, Health Care, Reports
Physicians agree that talking with patients about end-of-life and advance care planning is important, but many also said they’re often unsure what to ...
Senior Living Executive magazine spoke with geriatrician and memory care expert Dr. G. Allen Power about his philosophies on getting older and the rol...
Facts and Figures, Health and Wellness, Health Care, Medication Management
The majority of adults over 50 think prescription drugs are too expensive and most says it’s important for politicians to support efforts to make thes...
End of Life, Health and Wellness, Medication Management, Memory Care Best Practices and Research, Memory Care Education
The Administration for Community Living has developed a three-part set of materials on medications and the aging brain, available by clicking on the B...
Financing Senior Living – Consumer Education, Memory Care Best Practices and Research, Memory Care Education
Many relatives and friends providing financial support or care to individuals with dementia are dipping into their retirement savings and sold assets ...
ALFA Conference & Expo, ALFA Events, Business Planning, CEO, cheatsheet, Clinical Quality and Quality Care Delivery, Engage, Finance, Property Management
It’s the last week to register for the early bird rate for Argentum’s upcoming Senior Living Executive Conference. Staying abreast of industry chan...
Consumer Intelligence, End of Life, Health and Wellness, Reports
The increasing burden of chronic disease is the single most important threat to the health of American families and a drain on the U.S. economy, accor...